Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLD100-E
- Development stage
- Phase 2
- Lead developer
- Collegium Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HLD100-E is a specific modified-release formulation of dextroamphetamine sulfate developed by Ironshore Pharmaceuticals for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). It utilizes Ironshore's proprietary DELEXIS drug delivery technology, which is designed to provide a delayed-release and extended-release (DR/ER) profile. This platform consists of a functional film coating that allows for evening dosing with a significant delay in initial drug release, followed by a controlled extended release throughout the following day. This pharmacokinetic profile is intended to target early morning symptoms and maintain therapeutic efficacy throughout the day. HLD100-E was evaluated in Phase II clinical trials (such as NCT02341248) as part of an adaptive trial design to identify the optimal formulation for pediatric and adolescent patients.
- Other names
- dextroamphetamine sulfate modified-releaseHLD-100HLD100HLD 100
02
Targets
TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on HLD100-E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLD100-E.